Skip to main content
Atrás
Watch Compare

Spero Therapeutics, Inc.

Calidad de datos: 100%
SPRO
Nasdaq Manufacturing Chemicals
$2.79
▲ $0.07 (2.57%)
Cap. Mercado: 161.52 M
Precio
$2.79
Cap. Mercado
161.52 M
Rango del Día
$2.67 — $2.79
Rango de 52 Semanas
$0.52 — $3.22
Volumen
355,015
Apertura $2.72
Promedio 50D / 200D
$2.36
18.44% above
Promedio 50D / 200D
$2.32
20.01% above

Quick Summary

Puntos Clave

Revenue grew 38.31% annually over 5 years — strong growth
ROE of 28.90% indicates high profitability
Negative free cash flow of -12.62 M

Crecimiento

Revenue Growth (5Y)
38.31%
Above sector avg (1.82%)
Revenue (1Y)39.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
28.90%
Above sector avg (-53.41%)
ROIC13.97%
Net Margin12.83%
Op. Margin9.45%

Seguridad

Debt / Equity
N/A
Current Ratio3.83
Interest CoverageN/A

Valoración

PE (TTM)
18.84
Above sector avg (-1.48)
P/B Ratio6.10
EV/EBITDA17.88
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E 18.8 -1.5
P/B 6.1 1.6
ROE % 28.9 -53.4
Net Margin % 12.8 -41.5
Rev Growth 5Y % 38.3 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 39.24% Revenue Growth (3Y) -19.77%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -38.69%
Revenue Growth (5Y) 38.31% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 66.80 M Net Income (TTM) 8.57 M
ROE 28.90% ROA 14.74%
Gross Margin N/A Operating Margin 9.45%
Net Margin 12.83% Free Cash Flow (TTM) -12.62 M
ROIC 13.97% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.83
Interest Coverage N/A Asset Turnover 1.15
Working Capital 38.67 M Tangible Book Value 26.49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 18.84 Forward P/E N/A
P/B Ratio 6.10 P/S Ratio 2.42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 17.88 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7.82%
Market Cap 161.52 M Enterprise Value 112.90 M
Per Share
EPS (Diluted TTM) 0.15 Revenue / Share 1.15
FCF / Share -0.22 OCF / Share -0.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -147.27%
SBC-Adj. FCF -18.10 M Growth Momentum 0.93

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 66.80 M 47.98 M 103.78 M 53.51 M 18.26 M
Net Income 8.57 M -68.57 M 22.81 M -46.42 M -89.80 M
EPS (Diluted) 0.15 -1.27 0.43 -1.23 —
Gross Profit — — — — —
Operating Income 6.31 M -73.36 M 21.48 M -42.20 M -87.97 M
EBITDA — — — — —
R&D Expenses 38.47 M 96.76 M 51.44 M 47.59 M 64.53 M
SG&A Expenses — — — — —
D&A 0.0 2,000.0 367,000.0 869,000.0 646,000.0
Interest Expense — — — — —
Income Tax 261,000.0 0.0 2.60 M 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 68.92 M 110.54 M 182.39 M 124.80 M 171.07 M
Total Liabilities 9.90 M 64.42 M 75.50 M 48.87 M 82.78 M
Shareholders' Equity 59.02 M 46.12 M 106.89 M 75.93 M 88.29 M
Total Debt — — — — —
Cash & Equivalents 40.27 M 52.89 M 76.33 M 109.11 M 112.58 M
Current Assets 67.29 M 107.28 M 131.21 M 113.57 M 157.87 M
Current Liabilities 8.87 M 49.07 M 37.15 M 21.65 M 18.67 M